SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving intense market conversation following its historic IPO, which saw the company achieve a massive valuation on its first day of trading. Community discourse is sharply divided between retail investors optimistic about the stock's long-term potential for space and AI infrastructure, and skeptics who are highlighting the company's lack of profitability, high valuation relative to earnings, and the influence of heavy institutional buying.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP crypto is facing extreme volatility and intense community scrutiny, with investors polarized between those viewing it as a speculative play and many others calling it a scam. The discussion is dominated by concerns over massive value erosion, reports of historical front-running, and ongoing skepticism regarding the token's real-world utility compared to established digital assets.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following reports that the streaming company is exploring strategic options, including a potential sale to a U.S. media entity. Investors are actively debating the viability of these buyout rumors and discussing potential acquirers, while also keeping a close eye on the stock's strong technical momentum.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following shareholder approval of the $110 billion merger with Paramount Skydance, a move that is reshaping the streaming landscape while drawing ongoing scrutiny from regulators and industry creators. Investors are actively discussing the deal's path to completion, the impact of significant debt restructuring, and the potential competitive challenges the combined entity will face against industry giants.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as it navigates significant market volatility driven by a proposed public stock offering, occurring shortly after the company reported successful Phase 3 trial results for its HAE gene-editing therapy. The community is actively debating the strategic necessity of the dilution against the long-term potential of the company's CRISPR pipeline, with many retail traders expressing frustration over management's timing while bulls highlight institutional accumulation and the stock's massive short interest as potential catalysts for a future squeeze.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing high volatility as investors weigh a disappointing May sales report for YARTEMLEA against imminent catalysts, including potential EMA approval and upcoming J-code reimbursement updates. The community remains deeply divided, with some investors aggressively buying the dip on conviction of long-term value, while others express frustration over management's lack of communication regarding executive turnover and launch trajectory.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is facing heightened market scrutiny as the asset manager limits withdrawals from its private credit funds following record redemption requests, sparking broader investor concerns about liquidity in the private credit sector. The community is actively debating whether these restrictive redemption policies signal systemic risks within the $1.8 trillion private credit market or represent isolated issues regarding asset valuations and borrower stress.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargo is trending as market participants weigh the bank's expanded growth potential following the lift of its long-standing asset cap against recent earnings that missed revenue expectations. Investors are actively debating the stock's future amid management's pivot toward operational efficiency and new institutional offerings like options clearing, while technical analysts continue to scrutinize the price action around key technical support and resistance levels.

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending as investors react to BofA's upgrade and price target hike, which highlights significant growth potential from optical interconnects, LEO satellite partnerships, and a recovering automotive market. The community is actively discussing the stock's role as a key supplier to the SpaceX Starlink ecosystem, with some traders monitoring high-volume call activity and a "high tight flag" technical pattern.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh the highly anticipated R2 SUV launch against broader concerns regarding production scaling, profitability, and unfavorable lease pricing. While the community remains deeply divided between bulls citing the long-term potential of the R2 platform and bears focusing on weak execution and cash burn, sentiment is currently pressured by a wider market downturn and skepticism over whether the launch acts as a true turning point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.57% and -64.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +253.07% and +56.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommen...

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Time to Sell?

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9% - Here's What Happened...

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have earned an average rating of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat...

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

What is HC Wainwright's Forecast for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Thursday, March 12th. HC...

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

FHTXFoghorn Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FHTX News